Status:

WITHDRAWN

IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD

Lead Sponsor:

Wayne State University

Collaborating Sponsors:

Children's Hospital of Michigan

American Regent, Inc.

Conditions:

Iron Deficiency Anemia

Inflammatory Bowel Disease

Eligibility:

All Genders

12-17 years

Phase:

PHASE2

Brief Summary

The purpose of this study is to assess the safety and efficacy of intravenous iron sucrose in comparison to oral ferrous sulfate in improving iron deficiency anemia in children with inflammatory bowel...

Detailed Description

Iron deficiency anemia (IDA) is very common among children with inflammatory bowel disease. Causes in this population are multi-factorial, including decreased absorption due to intestinal disease, inc...

Eligibility Criteria

Inclusion

  • IBD Diagnosis.
  • IDA (defined as a hemoglobin (Hb) concentration of ≤10.5 g/dL females) or Hb ≤11.0 g/dL (males) and Mean Corpuscular volume (MCV) \< 77 \[22\] plus transferrin saturation (TSAT) \< 20% and/or serum ferritin concentration less than 25 µg/L)
  • 12- 17 years old males or females.
  • A signed parental permission and assent. Assent is not required in those below 13 years of age.
  • We will be including those who have received iron therapy in the past even if they have developed adverse reactions, as long as they have not been anaphylactic. Participants should have been "iron free" (no iron therapy - oral or IV) for two weeks prior to start of study.

Exclusion

  • Anemia other than IDA e.g hemolytic anemia, anemia due to Vitamin B12/Folic acid deficiency.
  • Blood transfusion or iron supplementation 2 two weeks or less before starting the study.
  • Iron overload.
  • Renal disease - on medications such as diuretics or blood pressure lowering medications. On renal replacement therapy.
  • Severe reactive airway disease - classified as severe/high-risk asthma
  • Significant cardiac disease - on cardiac medications, including symptomatic congenital cardiac anomalies or with arrhythmias.
  • Anaphylaxis/hypersensitivity reaction to ferrous sulfate and/or iron sucrose
  • Pregnant and nursing women. A serum pregnancy test will be performed at the start of the study and on days 1, 14, and 28. Patients aged 12 years of age and are found to be pregnant are considered victims of child abuse and will be reported to child protective services and the appropriate authorities.
  • Any other severe concurrent illness.

Key Trial Info

Start Date :

November 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2012

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT01438372

Start Date

November 1 2011

End Date

March 1 2012

Last Update

January 7 2014

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Children's Hospital of Michigan

Detroit, Michigan, United States, 48201